Reviva to Participate in the A.G.P. Healthcare Company Showcase
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on developing therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases, has announced its participation in the upcoming A.G.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on developing therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases, has announced its participation in the upcoming A.G.P. Healthcare Company Showcase. The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will engage in a fireside chat during the virtual event scheduled for May 21, 2025, at 2:00 p.m. EST.
Details
News Market Reaction – RVPH
The recorded move for RVPH in the trading session of this news was +7.40%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CUPERTINO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a fireside chat at the A.G.P. Healthcare Company Showcase, taking place virtually May 21, 2025.
A.G.P. Healthcare Company Showcase
Format: Fireside Chat
Date: Wednesday, May 21, 2025
Time: 2:00 p.m. EST
Location: Virtual
Webcast Link: Click Here
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva's pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.